Ronald E. Gress, M.D.
Dr. Ronald Gress pursues investigation in basic, translational and clinical transplant immunology. His studies focus on T cell reconstitution in humans who have had depletion of T cell populations by chemotherapy. With collaborators, Dr. Gress introduced IL-7 into clinical trials. These studies allowed identification of T cell receptor repertoire repair by IL-7 – the basis of new strategies to repair repertoire defects and immune deficiency commonly associated with aging. As Chief of the Experimental Transplantation and Immunology Branch, he oversees efforts to cure cancers through translational transplant therapies.
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-3332
Bethesda, MD 20892-1203
Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)Open - RecruitingNCI Protocol ID NCI-09-C-0053Investigator Ronald E. Gress, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Zetta Blacklock-Schuver 301.594.2056
The primary goals of the Transplantation Therapy Section are to generate new understandings in transplantation biology and to develop new transplantation therapies based on those basic science investigations. The section concentrates on efforts in four complementary areas:
- In the area of cellular hematopoiesis, investigations are carried out to characterize negative regulation; the clinical aim is to generate strategies for establishing effective hematopoiesis of progenitor cells manipulated in vivo or in vitro (including purging). These studies have delineated the regulatory role of IGF-II in CD34+ cell proliferation and have begun to characterize the role of chemokines as negative regulators of hematopoiesis.
- In the area of T cell regeneration, the goal of our studies is to characterize mechanisms of T cell reconstitution; clinically, the aim is to maximize T cell regeneration for therapeutic gain. We have found that efficient T cell regeneration is dependent on thymic activity, which varies inversely with age so that compromise exists even in young adults. In older adults, expansion of postthymic T cells accounts for the majority of CD4+ T cell reconstitution, but such T cell populations then tend to diminish with time. This latter observation has prompted our work to identify mechanisms by which expanded T cell populations are lost.
- Currently, we are studying the role of the SPATIAL gene in thymus function using mouse knockout model systems combined with cellular and molecular techniques. SPATIAL is specifically expressed in thymic subcapsular cells and our data suggests it negatively regulates thymic input of precursor cells. Our studies are focused on the following: regulation of SPATIAL function, the impact of SPATIAL on cell cycle control mechanisms, regulation of ubiquitination, stem cell migration into the thymus, intrathymic precursor cell proliferation, post bone marrow transplant T cell reconstitution, and differential gene expression in stromal cells. We plan to build on these experiments to develop new drugs to enhance thymus function and T cell reconstitution to improve human health following a period of immune deficiency.
- Current and planned clinical studies follow themes developed within the preceding projects with emphasis on the augmentation of T cell regeneration/responses. Current clinical studies focus on treatment of residual disease in patients with breast cancer and exploit the understanding that post-chemotherapy T cell regeneration in adults involves primarily extrathymic expansion, requires mature T cell progenitors, is antigen driven, is prone to skewing, and is cytokine regulated. Such studies also seek to characterize further the regeneration of T cells (especially CD8+ cells) in patients with cancer.
Selected Key Publications
- J. Exp. Med. 207: 2521-32, 2010. [ Journal Article ]
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.J. Exp. Med. 205: 1701-14, 2008. [ Journal Article ]
- J. Clin. Invest. 115: 930-9, 2005. [ Journal Article ]
Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor.J. Exp. Med. 191: 1187-96, 2000. [ Journal Article ]
- N. Engl. J. Med. 332: 143-9, 1995. [ Journal Article ]
Dr. Gress received his M.D. from Baylor College of Medicine and his internal medicine residency and oncology fellowship training at the Johns Hopkins Hospital and the NCI. His research interests have been in the area of transplantation immunology with emphasis on the regulation of allogeneic responses and the mechanisms by which peripheral lymphocyte populations are generated and maintained. Dr. Gress is also chief of the Medical Oncology Clinical Research Unit and head of the Transplantation Immunology Section, Experimental Immunology Branch.
|Hoda Abadeer||Biologist (Contr)|
|Caroelise Ataku||Biologist (Contr)|
|Daniele N. Avila M.S.N., C.R.N.P.||Nurse Practitioner|
|Fatima Awad||Biologist (Contr)|
|Catherine V. Bare||Technical Laboratory Manager|
|Judy L. Baruffaldi||Patient Care Coordinator (Contr)|
|Donald E. Farthing Ph.D.||Biochemist (Contr)|
|Francis A. Flomerfelt, Ph.D.||Staff Scientist|
|Alicia M. Guevara MBA||Program Analyst|
|Megan Kenyon||Physician Assistant|
|Hye Kyung Kim Ph.D.||Research Fellow|
|Jae Ho Kim||Postbaccalaureate Fellow (CRTA)|
|Philip J. Lucas, Ph.D.||Staff Scientist|
|Jennifer Mann N.P.||Nurse Practitioner|
|Sarfraz A. Memon M.D.||Research Chemist|
|Fred Rogers||Biologist (Contr)|
|Jean Sabes||Program Specialist|
|Laura Skeffington B,S,||Physician Assistant (Contr)|
|Ruifeng Teng Ph.D.||Scientist (Contr)|
|Jiun Wang Ph.D.||Research Biologist|
|Jennifer Wilder R.N.||Nurse Specialist (Contr)|